Alchemy

Executive Summary

Alchemy is a preclinical-stage biotechnology company headquartered in San Francisco, leveraging artificial intelligence and machine learning to transform drug delivery and small molecule discovery. Founded in 2019, the company's integrated platform combines computational models with experimental data to design novel therapeutics with improved pharmacokinetic and pharmacodynamic properties. Alchemy focuses on oncology and neurology, aiming to accelerate the development of treatments for complex diseases. As a Y Combinator-backed startup, Alchemy operates with a lean team of 1-50 employees and is privately held. While the company has not disclosed funding amounts or valuation, its AI-driven approach positions it within a rapidly growing sector of biotech innovation. The platform's potential to enhance precision and efficacy in drug design could address significant unmet medical needs, but the preclinical stage implies high technical and regulatory risk. Alchemy's progress will depend on successful validation of its computational models and securing partnerships or additional capital to advance its pipeline toward clinical development.

Upcoming Catalysts (preview)

• Q1 2027Series A Financing Round70% success
• Q4 2027First IND Filing for Lead Program40% success
• Q2 2027Major Pharma Partnership or Licensing Deal30% success